http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
BeiGene to Highlight Broad Oncology Portfolio at the 2023 ASCO Annual Meeting
-
BeiGene Announces Goals Focused on Sustainable Growth and Workforce Diversity in New ESG Report
-
BeiGene (BGNE) Announces Positive Phase 3 Tislelizumab Trial Results
-
BeiGene Announces Positive Phase 3 Tislelizumab Trial in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
-
BeiGene and SpringWorks Present Clinical Data on Lifirafenib, in Combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Assoc
-
SpringWorks and BeiGene Present Clinical Data on Lifirafenib, in combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Assoc
-
MapKure, SpringWorks and BeiGene Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association
-
MapKure, BeiGene and SpringWorks Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association
-
BeiGene Expands Presence in Latin America With Opening of Brazil Office
-
BeiGene Appoints Julius Pryor III as First Global Head of Diversity and Health Equity
-
BeiGene (BGNE) Enters New Phase to Expand US Manufacturing and R&D Footprint in New Jersey
-
BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New Jersey
-
BeiGene Reports Fourth Quarter and Full Year 2022 Financial Results
-
BeiGene (BGNE) Receives 10th Approval for PD-1 Inhibitor Tislelizumab in China
-
BeiGene to Present at Cowen’s 43rd Annual Healthcare Conference
-
BeiGene Receives 10th Approval for PD-1 Inhibitor Tislelizumab in China
-
New Talk About It Resources Aim to Accelerate Integration of Mental Health into Quality Cancer Care
-
BeiGene to Present at Upcoming Investor Conferences
-
BRUKINSA® Approved in the U.S. for Chronic Lymphocytic Leukemia
-
BRUKINSA® (zanubrutinib) Receives Marketing Authorization for Chronic Lymphocytic Leukemia (CLL) and Marginal Zone Lymphoma (MZL) in Great Britain by MHRA
-
BeiGene (BGNE) Announces Expansion of Coverage on China’s National Reimbursement Drug List
-
BeiGene Announces Expansion of Coverage on China’s National Reimbursement Drug List
-
BeiGene Presents New Research from Tislelizumab Global Development Program at 2023 ASCO Gastrointestinal Cancers Symposium
-
BeiGene to Present at the J.P. Morgan 41st Annual Healthcare Conference
-
BeiGene Announces Acceptance of 12th Regulatory Submission in China for PD-1 Inhibitor Tislelizumab
-
BeiGene's (BGNE) BRUKINSA Demonstrated Superior PFS Over IMBRUVICA in Chronic Lymphocytic Leukemia in Late-Breaker at ASH
-
BeiGene’s BRUKINSA® (zanubrutinib) Demonstrated Superior Progression-Free Survival Over IMBRUVICA® (ibrutinib) in Chronic Lymphocytic Leukemia in Late-Breaker at ASH
-
BeiGene Calls for Greater Integration of Mental Health in Cancer Care After New Survey Reveals Gaps/Barriers for Patients and Survivors
-
BeiGene to Present Final PFS Results from ALPINE Trial Demonstrating Superior PFS for BRUKINSA® Versus IMBRUVICA® in Late-Breaking Oral Session at ASH 2022
-
BeiGene (BGNE) Announces EU Approval of BRUKINSA for Treatment of Adults with CLL
-
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Chronic Lymphocytic Leukemia (CLL)
-
BeiGene Launches Talk About It Program to Elevate the Importance of Addressing Mental Health during Cancer Care
-
BeiGene Announces Brazil Approvals for BRUKINSA® As a Treatment for Rare Blood Cancers
-
BeiGene Reports Third Quarter 2022 Financial Results
-
BeiGene to Present at Upcoming Investor Conferences
-
BeiGene to Present Dynamic View of Development Programs for Hematologic Malignancies at 64th ASH Meeting
-
BeiGene (BGNE) Granted EU Approval of BRUKINSA for Treatment of Adults with Marginal Zone Lymphoma
-
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma
-
BeiGene (BGNE) Announces BRUKINSA Approvals in Latin America
-
BeiGene Expands Reach of its Innovative BTK Inhibitor with Recent Regulatory Approvals in Latin America
-
BeiGene (BGNE) Announces Positive CHMP Opinion for BRUKINSA for Treatment of Adults With CLL
-
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults With CLL
-
BeiGene (BGNE) Announces Positive Topline Results from Final PFS Analysis of BRUKINSA Compared to IMBRUVICA in Phase 3 CLL Trial
-
BeiGene Announces Positive Topline Results from Final Progression-Free Survival Analysis of BRUKINSA® (zanubrutinib) Compared to IMBRUVICA® (ibrutinib) in Phase 3 Chronic Lymphocytic Leukemia (CLL)
-
BeiGene (BGNE) Announces NICE Recommended BRUKINSA for Patients with Waldenstrom’s Macroglobulinemia
-
NICE Recommends BeiGene’s BRUKINSA® (zanubrutinib) for Patients with Waldenström’s Macroglobulinemia who have had at Least One Treatment
-
BeiGene (BGNE) Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma
-
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma
-
BeiGene Announces Data Presentations at ESMO 2022 Including Late-Breaking Oral Presentation for Tislelizumab in First-Line Unresectable Hepatocellular Cancer
-
BeiGene to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
